Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.

T. Cornelis*, E.A. Beckers, A.L.C. Driessen, F.M. van der Sande, G.H. Koek

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

9 Citations (Web of Science)


Context. Bortezomib is a proteasome inhibitor with excellent antimyeloma activity. The most frequent toxic side effects are gastrointestinal, neuropathy and thrombocytopenia. The liver was not considered an important target organ for toxicity until one case of bortezomib-induced severe hepatitis was reported in a patient with multiple myeloma. Case report. We describe a patient developing acute cholestatic and parenchymal hepatitis complicated by fatal liver failure after bortezomib therapy for multiple myeloma. Discussion: The importance of being aware of this potential fatal complication is emphasized considering that this drug is increasingly prescribed and in order to discontinue this drug if liver adverse reaction is suspected.
Original languageEnglish
Pages (from-to)444-445
JournalClinical Toxicology
Issue number5
Publication statusPublished - 1 Jan 2012

Cite this